Register      Login
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
Shopping Cart: ( empty )
You are here: Home > Journals > SH > SH10006
REVIEW
Contents Vol 7(3)

Unresolved questions concerning human papillomavirus infection and transmission: a modelling perspective

David G. Regan A C , David J. Philp B and Edward K. Waters A
+ Author Affiliations
- Author Affiliations

A The National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Building CC4, 45 Beach Street, Coogee, NSW 2034, Australia.

B School of Public Health and Community Medicine, The University of New South Wales, Sydney, NSW 2052, Australia.

C Corresponding author. Email: dregan@nchecr.unsw.edu.au

Sexual Health 7(3) 368-375 https://doi.org/10.1071/SH10006
Submitted: 21 January 2010  Accepted: 3 June 2010   Published: 19 August 2010

Abstract

Mathematical transmission models are widely used to forecast the potential impact of interventions such as vaccination and to inform the development of health policy. Effective vaccines are now available for the prevention of cervical cancer and other diseases attributable to human papillomavirus (HPV). Considerable uncertainties remain regarding the characterisation of HPV infection and its sequelae, infectivity, and both vaccine-conferred and naturally-acquired immunity. In this review, we discuss the key knowledge gaps that impact on our ability to develop accurate models of HPV transmission and vaccination.

Additional keywords: dynamic model, infectiousness, knowledge gaps, mathematical transmission model, vaccination.


References


[1] Muñoz N,  Manalastas R,  Pitisuttithum P,  Tresukosol D,  Monsonego J,  Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet 2009; 373 1949–57.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[2] Paavonen J,  Naud P,  Salmeron J,  Wheeler C,  Chow SN,  Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374 301–14.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[3] The GlaxoSmithKline Vaccine HPV-007 Study Group Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374 1975–85.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[4] Wheeler CM,  Kjaer SK,  Sigurdsson K,  Iversen OE,  Hernandez-Avila M,  Perez G, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J Infect Dis 2009; 199 936–44.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[5] Stanley M. Prospects for new human papillomavirus vaccines. Curr Opin Infect Dis 2010; 23 70–5.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[6] Brisson M,  Van de Velde N,  Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009; 12 343–51.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[7] Marra F,  Cloutier K,  Oteng B,  Marra C,  Ogilvie G. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 2009; 27 127–47.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[8] Dasbach EJ,  Elbasha EH,  Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006; 28 88–100.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[9] Kim SY,  Goldie SJ. Cost-effectiveness analyses of vaccination programmes – a focused review of modelling approaches. Pharmacoeconomics 2008; 26 191–215.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[10] Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005; 191 S97–106.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[11] Garnett GP. An introduction to mathematical models in sexually transmitted disease epidemiology. Sex Transm Infect 2002; 78 7–12.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[12] Anderson RM , May RM . Infectious diseases of humans: dynamics and control. New York: Oxford University Press; 1991.

[13] Garnett GP,  Anderson RM. Sexually transmitted diseases and sexual behavior: insights from mathematical models. J Infect Dis 1996; 174 S150–61.
| PubMed |

[14] Keeling MJ , Rohani P . Modeling infectious diseases in humans and animals. Princeton: Princeton University Press; 2008.

[15] Brunham RC. Insights into the epidemiology of sexually transmitted diseases from R 0 = βcd. Sex Transm Dis 2005; 32 722–4.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[16] Giuliano AR,  Anic G,  Nyitray AG. Epidemiology and pathology of HPV disease in males. Gynecol Oncol 2010; 117 S15–9.
| Crossref | GoogleScholarGoogle Scholar |

[17] de Visser RO,  Smith AM,  Rissel CE,  Richters J,  Grulich AE. Sex in Australia: heterosexual experience and recent heterosexual encounters among a representative sample of adults. Aust N Z J Public Health 2003; 27 146–54.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[18] Johnson AM,  Mercer CH,  Erens B,  Copas AJ,  McManus S,  Wellings K, et al. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet 2001; 358 1835–42.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[19] Laumann EO , Gagnon JH , Michael RT , Michaels S . The social organisation of sexuality: sexual practices in the United States. Chicago: University of Chicago Press; 2000.

[20] Smith AMA,  Rissel CE,  Richters J,  Grulich AE,  de Visser RO. Australian study of health and relationships. Aust N Z J Public Health 2003; 27 103–256.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[21] Giuliano AR,  Harris R,  Sedjo RL,  Baldwin S,  Roe D,  Papenfuss MR, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women’s Health Study. J Infect Dis 2002; 186 462–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[22] Giuliano AR,  Lu B,  Nielson CM,  Flores R,  Papenfuss MR,  Lee JH, et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 2008; 198 827–35.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[23] Trottier H,  Mahmud S,  Prado JCM,  Sobrinho JS,  Costa MC,  Rohan TE, et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis 2008; 197 1436–47.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[24] Bleeker MC,  Hogewoning CJ,  Berkhof J,  Voorhorst FJ,  Hesselink AT,  van Diemen PM, et al. Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin Infect Dis 2005; 41 612–20.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[25] Hernandez BY,  Wilkens LR,  Zhu X,  Thompson P,  McDuffie K,  Shvetsov YB, et al. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis 2008; 14 888–94.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[26] Rowhani-Rahbar AMM,  Hughes JPP,  Koutsky LAP. Difficulties in estimating the male-to-female sexual transmissibility of human papillomavirus infection. Sex Transm Dis 2009; 36 261–3.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[27] Brink AATP,  Snijders PJF,  Meijer CJLM. HPV detection methods. Dis Markers 2007; 23 273–81.
| PubMed |

[28] Iftner T,  Villa LL. Chapter 12: human papillomavirus technologies. J Nat Cancer Inst Mono 2003; 31 80–8.


[29] Keegan H,  Mc Inerney J,  Pilkington L,  Grønn P,  Silva I,  Karlsen F, et al. Comparison of HPV detection technologies: hybrid capture 2, PreTect™ HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens. J Virol Methods 2009; 155 61–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[30] Lorincz AT. Molecular methods for the detection of human papillomavirus infection. Obstet Gynecol Clin North Am 1996; 23 707–30.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[31] Villa LL,  Denny L. Chapter 7: methods for detection of HPV infection and its clinical utility. Int J Gynaecol Obstet 2006; 94 S71–80.
| Crossref | GoogleScholarGoogle Scholar |

[32] Zaravinos A,  Mammas IN,  Sourvinos G,  Spandidos DA. Molecular detection methods of human papillomavirus (HPV). Int J Biol Markers 2009; 24 215–22.
| PubMed |

[33] Hopman AH,  Smedts F,  Dignef W,  Ummelen M,  Sonke G,  Mravunac M, et al. Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. J Pathol 2004; 202 23–33.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[34] Molden T,  Kraus I,  Karlsen F,  Skomedal H,  Nygard JF,  Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 2005; 14 367–72.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[35] Shi W,  Kato H,  Perez-Ordonez B,  Pintilie M,  Huang S,  Hui A, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009; 27 6213–21.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[36] Tinelli A,  Leo G,  Pisanò M,  Storelli F,  Leo S,  Vergara D, et al. HPV viral activity by mRNA-HPV molecular analysis to screen the transforming infections in precancer cervical lesions. Curr Pharm Biotechnol 2009; 10 767–71.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[37] Wang-Johanning F,  Lu DW,  Wang Y,  Johnson MR,  Johanning GL. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer 2002; 94 2199–210.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[38] Winer RL,  Harris TG,  Xi LF,  Jansen KU,  Hughes JP,  Feng Q, et al. Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development. J Med Virol 2009; 81 713–21.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[39] Kösel S,  Burggraf S,  Engelhardt W,  Olgemoller B. Increased levels of HPV16 E6*I transcripts in high-grade cervical cytology and histology (CIN II+) detected by rapid real-time RT-PCR amplification. Cytopathology 2007; 18 290–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[40] Peto J,  Gilham C,  Deacon J,  Taylor C,  Evans C,  Binns W, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004; 91 942–53.
| PubMed |

[41] Newall AT,  Brotherton JML,  Quinn HE,  McIntyre PB,  Backhouse J,  Gilbert L, et al. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin Infect Dis 2008; 46 1647–55.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[42] Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008; 109 S15–21.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[43] Wang SS,  Schiffman M,  Shields TS,  Herrero R,  Hildesheim A,  Bratti MC, et al. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica. Br J Cancer 2003; 89 1248–54.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[44] Rissel CE,  Richters J,  Grulich AE,  de Visser RO,  Smith AM. Sex in Australia: first experiences of vaginal intercourse and oral sex among a representative sample of adults. Aust N Z J Public Health 2003; 27 131–7.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[45] Grulich AE,  van Leeuwen MT,  Falster MO,  Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370 59–67.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[46] Vajdic CM,  van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009; 125 1747–54.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[47] Schulz TF. Cancer and viral infections in immunocompromised individuals. Int J Cancer 2009; 125 1755–63.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[48] Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 2009; 384 410–4.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[49] Stanley MA. Immune responses to human papilloma viruses. Indian J Med Res 2009; 130 266–76.
| PubMed |

[50] Jit M,  Choi YH,  Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337 a769.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[51] Goldie SJ,  Kohli M,  Grima D,  Weinstein MC,  Wright TC,  Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96 604–15.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[52] Myers ER,  McCrory DC,  Nanda K,  Bastian L,  Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000; 151 1158–71.
| PubMed |

[53] Sanders GD,  Taira AV. Cost effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9 37–48.
| PubMed |

[54] Barnabas RV,  Laukkanen P,  Koskela P,  Kontula O,  Lehtinen M,  Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006; 3 e138.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[55] Hughes JP,  Garnett GP,  Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002; 13 631–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[56] Partridge JM,  Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis 2006; 6 21–31.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[57] Regan DG,  Philp DJ,  Hocking JS,  Law MG. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sex Health 2007; 4 147–63.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[58] Brown DR,  Kjaer SK,  Sigurdsson K,  Iversen OE,  Hernandez-Avila M,  Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 2009; 199 926–35.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[59] Haupt RM . Gardasil update: efficacy and safety in boys and men. Available online at: http://www.cdc.gov/vaccines/recs/ACIP/downloads/mtg-slides-jun09/06-2-hpv.pdf[verified June 2010].

[60] Mao C,  Koutsky LA,  Ault KA,  Wheeler CM,  Brown DR,  Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia – a randomized controlled trial. Obstet Gynecol 2006; 107 18–27.
| PubMed |

[61] Rowhani-Rahbar A,  Mao C,  Hughes JP,  Alvarez FB,  Bryan JT,  Hawes SE, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 2009; 27 5612–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[62] Olsson SE,  Villa LL,  Costa RL,  Petta CA,  Andrade RP,  Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25 4931–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[63] Cuzick J,  Castanon A,  Sasieni P. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20–29 in the UK. Br J Cancer 2010; 102 933–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[64] Dobson S , Dawar M , Scheifele D , Kollmann T , McNeil S , Halperin S et al Are 2 doses of HPV vaccine adequate in girls? 25th International Papillomavirus Conference; 2009, Malmo, Sweden.

[65] International Agency for Research on Cancer. Randomized trial of 2 versus 3 doses of HPV vaccine in India. Lyon: IARC; 2010. Available online at: http://screening.iarc.fr/hpvvaccine.php[verified May 2010].

[66] Burchell AN,  Winer RL,  de Sanjose S,  Franco EL. Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006; 24 S52–61.
| Crossref | GoogleScholarGoogle Scholar |

[67] D’Souza G,  Agrawal Y,  Halpern J,  Bodison S,  Gillison ML. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009; 199 1263–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[68] Goodman M,  Shvetsov Y,  McDuffie K,  Wilkens L,  Zhu X,  Ning L, et al. Acquisition of anal human papillomavirus (HPV) infection in women: the Hawaii HPV cohort study. J Infect Dis 2008; 197 957–66.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[69] Nyitray AG,  Smith D,  Villa L,  Lazcano-Ponce E,  Abrahamsen M,  Papenfuss M, et al. Prevalence of and risk factors for anal human papillomavirus infection in men who have sex with women: a cross-national study. J Infect Dis 2010;
| Crossref | GoogleScholarGoogle Scholar |

[70] Goodman MT,  Shvetsov YB,  McDuffie K,  Wilkens LR,  Zhu X,  Thompson PJ, et al. Sequential acquisition of human papillomavirus (HPV) infection of the anus and cervix: the Hawaii HPV cohort study. J Infect Dis 2010;
| Crossref | GoogleScholarGoogle Scholar |

[71] Piketty C,  Darragh TM,  Costa MD,  Bruneval P,  Heard I,  Kazatchkine MD, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003; 138 453–9.
| PubMed |

[72] Edwards S,  Carne C. Oral sex and the transmission of viral STIs. Sex Transm Infect 1998; 74 6–10.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[73] Bajos N,  Bozon M,  Beltzer N,  Laborde C,  Andro A,  Ferrand M, et al. Changes in sexual behaviours: from secular trends to public health policies. AIDS 2010; 24 1185–91.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[74] Chambers WC. Oral sex: varied behaviors and perceptions in a college population. J Sex Res 2007; 44 28–42.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[75] Remez L. Oral sex among adolescents: is it sex or is it abstinence? Fam Plann Perspect 2000; 32 298–304.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[76] Herrero R,  Castellsague X,  Pawlita M,  Lissowska J,  Kee F,  Balaram P, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003; 95 1772–83.
| PubMed |

[77] Maden C,  Beckmann AM,  Thomas DB,  McKnight B,  Sherman KJ,  Ashley RL, et al. Human papillomaviruses, herpes simplex viruses, and the risk of oral cancer in men. Am J Epidemiol 1992; 135 1093–102.
| PubMed |

[78] Castellsagué X,  Albero G,  Cleries R,  Bosch FX. HPV and circumcision: a biased, inaccurate and misleading meta-analysis. J Infect 2007; 55 91–3.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[79] Van Howe RS. Reply to “HPV and circumcision: a biased, inaccurate and misleading meta-analysis”. J Infect 2007; 55 93–6.
| Crossref | GoogleScholarGoogle Scholar |

[80] Van Howe RS. Human papillomavirus and circumcision: a meta-analysis. J Infect 2007; 54 490–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[81] Castellsague X,  Bosch FX,  Munoz N,  Meijer CJ,  Shah KV,  de Sanjose S, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002; 346 1105–12.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[82] Auvert B,  Sobngwi-Tambekou J,  Cutler E,  Nieuwoudt M,  Lissouba P,  Puren A, et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis 2009; 199 14–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[83] Frisch M,  Friis S,  Kjaer SK,  Melbye M. Falling incidence of penis cancer in an uncircumcised population (Denmark 1943–90). BMJ 1995; 311 1471.
| PubMed |

[84] Gray RH,  Serwadda D,  Kong X,  Makumbi F,  Kigozi G,  Gravitt PE, et al. Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis 2010; 201 1455–62.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[85] Madsen BS,  van den Brule AJC,  Jensen HL,  Wohlfahrt J,  Frisch M. Risk factors for squamous cell carcinoma of the penis – population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 2008; 17 2683–91.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[86] Tobian AA,  Serwadda D,  Quinn TC,  Kigozi G,  Gravitt PE,  Laeyendecker O, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009; 360 1298–309.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[87] Van Howe RS. Sampling bias explains association between human papillomavirus and circumcision. J Infect Dis 2009; 200 832.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[88] Viscidi RP,  Shah KV. Adult male circumcision: will it reduce disease caused by human papillomavirus? J Infect Dis 2010; 201 1447–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[89] Manhart LE,  Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? Sex Transm Dis 2002; 29 725–35.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[90] Ho GYF,  Kadish AS,  Burk RD,  Basu J,  Palan PR,  Mikhail M, et al. HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. Int J Cancer 1998; 78 281–5.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[91] Wen LM,  Estcourt CS,  Simpson JM,  Mindel A. Risk factors for the acquisition of genital warts: are condoms protective? Sex Transm Infect 1999; 75 312–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[92] Hogewoning CJ,  Bleeker MC,  van den Brule AJ,  Voorhorst FJ,  Snijders PJ,  Berkhof J, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003; 107 811–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[93] Bleeker MC,  Hogewoning CJ,  Voorhorst FJ,  van den Brule AJ,  Snijders PJ,  Starink TM, et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int J Cancer 2003; 107 804–10.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[94] Shew ML,  Fortenberry JD,  Tu W,  Juliar BE,  Batteiger BE,  Qadadri B, et al. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med 2006; 160 151–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[95] Winer RL,  Hughes JP,  Feng Q,  O’Reilly S,  Kiviat NB,  Holmes KK, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354 2645–54.
| Crossref | GoogleScholarGoogle Scholar | PubMed |